Millennium Management LLC has recently announced that it has increased stake in Aprea Therapeutics Inc. (NASDAQ:APRE) by 1,083.16%. After grabbing 0.12 million shares, the institutional investor is now in possession of 0.11 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.23% having worth around $50353.0. Moreover, BNP Paribas Arbitrage SNC increased its share by 61847.0 to have a control over 61847.0 shares.
Aprea Therapeutics Inc. (APRE) concluded trading on 01/11/23 at a closing price of $0.51, with 2.57 million shares of worth about $1.31 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -48.65% during that period and on Wednesday the price saw a gain of about 11.99%. Currently the company’s common shares owned by public are about 53.00M shares, out of which, 41.30M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the APRE stock and their offered price forecasts bring an average price target of $3.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $3.00 and could fall to a lowest price of $3.00. The stock’s current price level is 83.0% above of average price target set by the analysts, while a rise to estimated low would result in gain of 83.0% for the stock. However, touching the estimated high of $3.00 would mean a gain of 83.0% for the stock.
Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Vanguard Total Stock Market Index are the top 3 mutual funds which are holding stakes in Aprea Therapeutics Inc. Vanguard Extended Market Index Fu is currently holding 0.19 million shares of worth totaling $77634.0. The company recently came buying 0.0 shares which brought its stake up to 0.35% of the company’s outstanding shares. Vanguard Total Stock Market Index, after buying 99800.0 shares, have now control over 0.19% of the stake in the company. It holds 0.0 shares of worth $41417.0.
Aprea Therapeutics Inc. (NASDAQ: APRE) started trading at $0.49, above $0.03 from concluding price of the previous day. However, the stock later moved at a day high price of 0.5300, or with a gain of 11.99%. Stock saw a price change of 29.41% in past 5 days and over the past one month there was a price change of -1.92%. Year-to-date (YTD), APRE shares are showing a performance of 54.08% which decreased to -81.72% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.30 but also hit the highest price of $2.95 during that period. The average intraday trading volume for Aprea Therapeutics Inc. shares is 142.77K. The stock is currently trading 30.93% above its 20-day simple moving average (SMA20), while that difference is up 12.47% for SMA50 and it goes to -41.05% lower than SMA200.
Millennium Management LLC acquired 0.12 million shares of Aprea Therapeutics Inc. having value of about $50353.0. Data submitted at the U.S SEC by Millennium Management LLC revealed that the firm now holds 0.11 million shares in the company valued at close to $56649.78, or have control over 1,083.16% stake in the company. Aprea Therapeutics Inc. (NASDAQ: APRE) currently have 53.00M outstanding shares and institutions hold larger chunk of about 7.70% of that. Holding of mutual funds in the company is about 16.83% while other institutional holders and individual stake holders have control over 2.26% and 0.93% of the stake respectively.
The stock has a current market capitalization of $30.53M. It has posted earnings per share of -$5.17 in the same period. It has Quick Ratio of 8.40 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for APRE, volatility over the week remained 15.27% while standing at 13.53% over the month.
Analysts are in expectations that Aprea Therapeutics Inc. (APRE) stock would likely to be making an EPS of -$0.27 in the current quarter, while forecast for next quarter EPS is -$0.29 and it is -$1.22 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.46 which is -$0.09 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.45 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 31.10% while it is estimated to increase by 87.30% in next year.
Analysts at 2 brokerage firms have issued recommendations for the Aprea Therapeutics Inc. (APRE)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.50. Out of those 2 Wall Street analysts, 2 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Coverage by Berenberg stated Aprea Therapeutics Inc. (APRE) stock as a Buy in their note to investors on December 16, 2020, suggesting a price target of $37 for the stock. On September 29, 2020, JP Morgan Resumed their recommendations, while on June 22, 2020, H.C. Wainwright Initiated their ratings for the stock with a price target of $30. Stock get an Outperform rating from Robert W. Baird on April 21, 2020.